Psychotic Disorders

• 

  Subject Areas on Research

  • 3-Hydroxykynurenine and clinical symptoms in first-episode neuroleptic-naive patients with schizophrenia. 
  • A Multicenter, Rater-Blinded, Randomized Controlled Study of Auditory Processing-Focused Cognitive Remediation Combined With Open-Label Lurasidone in Patients With Schizophrenia and Schizoaffective Disorder. 
  • A comparison of stereology and segmentation techniques for volumetric measurements of lateral ventricles in magnetic resonance imaging. 
  • A follow-up study of post partum illness, 1946-1978. 
  • A longitudinal study of neurocognitive function in individuals at-risk for psychosis. 
  • A pilot study of a weight management program with food provision in schizophrenia. 
  • A pilot study of assertive community treatment for patients with chronic psychotic disorders. 
  • A population-based cohort study of premorbid intellectual, language, and behavioral functioning in patients with schizophrenia, schizoaffective disorder, and nonpsychotic bipolar disorder. 
  • A randomized controlled trial of allopurinol vs. placebo added on to antipsychotics in patients with schizophrenia or schizoaffective disorder. 
  • A randomized controlled trial of outpatient commitment in North Carolina. 
  • A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: comparison of antipsychotics for metabolic problems (CAMP). 
  • A research network to evaluate assertive community treatment: introduction. 
  • A scoring system derived from electronic health records to identify patients at high risk for noninvasive ventilation failure. 
  • A single assessment with the Brief Adherence Rating Scale (BARS) discriminates responders to long-acting injectable antipsychotic treatment in patients with schizophrenia. 
  • ACR Appropriateness Criteria® Acute Mental Status Change, Delirium, and New Onset Psychosis. 
  • Abnormalities of the corpus callosum in nonpsychotic children with chromosome 22q11 deletion syndrome. 
  • Actigraphic-measured sleep disturbance predicts increased positive symptoms in adolescents at ultra high-risk for psychosis: A longitudinal study. 
  • Acute psychotic disorder after gastric bypass surgery: differential diagnosis and treatment. 
  • Adolescents at clinical-high risk for psychosis: Circadian rhythm disturbances predict worsened prognosis at 1-year follow-up. 
  • Aggression and psychopathology in treatment-resistant inpatients with schizophrenia and schizoaffective disorder. 
  • Alteration of accessibility with scopolamine. 
  • Altered striatal functional connectivity in subjects with an at-risk mental state for psychosis. 
  • An evidence synthesis of care models to improve general medical outcomes for individuals with serious mental illness: a systematic review. 
  • An obsessional variant of capgras symptom: a case report. 
  • Anticipating DSM-V: opportunities and challenges for cognition and psychosis. 
  • Antidepressant drug therapy in psychotic depression. 
  • Antipsychotic-induced weight gain and therapeutic response: a differential association. 
  • Antipsychotics and the risk of sudden cardiac death. 
  • Assessing the New York City involuntary outpatient commitment pilot program. 
  • Association Between P300 Responses to Auditory Oddball Stimuli and Clinical Outcomes in the Psychosis Risk Syndrome. 
  • Association of Air Pollution Exposure in Childhood and Adolescence With Psychopathology at the Transition to Adulthood. 
  • Association of neuropsychiatric symptoms and sub-syndromes with cognitive impairment in community-dwelling Asian elderly. 
  • Associations between residence at birth and mental health disorders: a spatial analysis of retrospective cohort data. 
  • Attention deficit hyperactivity disorder symptoms as antecedents of later psychotic outcomes in 22q11.2 deletion syndrome. 
  • Autism, Psychosis, or Both? Unraveling Complex Patient Presentations. 
  • BDNF Val66Met and spontaneous dyskinesias in non-clinical psychosis. 
  • Behavioral response inhibition in psychotic disorders: diagnostic specificity, familiality and relation to generalized cognitive deficit. 
  • Bifactor and item response theory analyses of interviewer report scales of cognitive impairment in schizophrenia. 
  • Brain volumes in psychotic youth with schizophrenia and mood disorders. 
  • COVID-19-associated brief psychotic disorder. 
  • Can IQ moderate the response to cognitive remediation in people with schizophrenia? 
  • Can involuntary outpatient commitment reduce hospital recidivism?: Findings from a randomized trial with severely mentally ill individuals. 
  • Candidate neuroanatomic substrates of psychosis in old-aged depression. 
  • Case 14-2016: A Woman with a Thyroid Nodule and Psychosis. 
  • Cerebellar networks in individuals at ultra high-risk of psychosis: impact on postural sway and symptom severity. 
  • Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics. 
  • Characteristics of third-party money management for persons with psychiatric disabilities. 
  • Characterization of Severe and Extreme Behavioral Problems in Patients With Alternating Hemiplegia of Childhood. 
  • Childhood origins of violent behaviour in adults with schizophreniform disorder. 
  • Childhood trauma and children's emerging psychotic symptoms: A genetically sensitive longitudinal cohort study. 
  • Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. 
  • Cholinesterase inhibitors as adjunctive therapy in patients with schizophrenia and schizoaffective disorder: a review and meta-analysis of the literature. 
  • Clinical characteristics of Kraepelinian schizophrenia: replication and extension of previous findings. 
  • Clinical, demographic and social characteristics of psychotic depression. 
  • Clozapine-induced electroencephalogram changes as a function of clozapine serum levels. 
  • Cognitive burden of anticholinergic medications in psychotic disorders. 
  • Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome. 
  • Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). 
  • Community adjustment among the elderly: psychopharmacological patterns and diagnoses. 
  • Comorbid posttraumatic stress disorder is associated with suicidality in male veterans with schizophrenia or schizoaffective disorder. 
  • Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol. 
  • Comparative efficacy and safety of atypical and conventional antipsychotic drugs in first-episode psychosis: a randomized, double-blind trial of olanzapine versus haloperidol. 
  • Comparative mortality risks of antipsychotic medications in community-dwelling older adults. 
  • Comparing experiential acceptance and cognitive reappraisal as predictors of functional outcome in individuals with serious mental illness. 
  • Comparison of seizure duration, ictal EEG, and cognitive effects of ketamine and methohexital anesthesia with ECT. 
  • Competence to complete psychiatric advance directives: effects of facilitated decision making. 
  • Completing the puzzle: The search for pieces in the understanding of psychosis risk in 22q11.2 deletion syndrome. 
  • Corticolimbic brain anomalies are associated with cognitive subtypes in psychosis: A longitudinal study. 
  • Cost effectiveness of maintenance ECT. 
  • Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia. 
  • Criminal victimization of persons with severe mental illness. 
  • Cumulative Effects of Neighborhood Social Adversity and Personal Crime Victimization on Adolescent Psychotic Experiences. 
  • Deep-vein thrombosis with antipsychotic drugs. 
  • Deficits in auditory predictive coding in individuals with the psychosis risk syndrome: Prediction of conversion to psychosis. 
  • Deficits in generalized cognitive ability, visual sensorimotor function, and inhibitory control represent discrete domains of neurobehavioral deficit in psychotic disorders. 
  • Deviation from expected cognitive ability across psychotic disorders. 
  • Diagnostic utility of the dexamethasone suppression test. 
  • Disrupted salience network functional connectivity and white-matter microstructure in persons at risk for psychosis: findings from the LYRIKS study. 
  • Dissemination of evidence-based mental health interventions: importance to the trauma field. 
  • Does involuntary outpatient commitment lead to more intensive treatment? 
  • Drug interaction between carbapenems and extended-release divalproex sodium in a patient with schizoaffective disorder. 
  • Duration of untreated psychosis and the pathway to care in KwaZulu-Natal, South Africa. 
  • Economic inequality is related to cross-national prevalence of psychotic symptoms. 
  • Effect of ECT treatment number on the ictal EEG. 
  • Effectiveness of lurasidone in patients with schizophrenia or schizoaffective disorder switched from other antipsychotics: a randomized, 6-week, open-label study. 
  • Effectiveness of switching from antipsychotic polypharmacy to monotherapy. 
  • Effects of clozapine, olanzapine, risperidone, and haloperidol on hostility among patients with schizophrenia. 
  • Effects of olanzapine, quetiapine, and risperidone on neurocognitive function in early psychosis: a randomized, double-blind 52-week comparison. 
  • Efficacy and safety of donepezil in patients with schizophrenia or schizoaffective disorder: significant placebo/practice effects in a 12-week, randomized, double-blind, placebo-controlled trial. 
  • Efficacy and tolerability of olanzapine, quetiapine, and risperidone in the treatment of early psychosis: a randomized, double-blind 52-week comparison. 
  • Electroconvulsive therapy in the presence of brain tumor. Case reports and an evaluation of risk. 
  • Elevated antisaccade error rate as an intermediate phenotype for psychosis across diagnostic categories. 
  • Emotion recognition and social/role dysfunction in non-clinical psychosis. 
  • Endorsement of personal benefit of outpatient commitment among persons with severe mental illness. 
  • Etiological and clinical features of childhood psychotic symptoms: results from a birth cohort. 
  • Etiological features of borderline personality related characteristics in a birth cohort of 12-year-old children. 
  • Evaluation of Proactive Community Case Detection to Increase Help Seeking for Mental Health Care: A Pragmatic Randomized Controlled Trial. 
  • Eveningness chronotype preference among individuals at clinical high risk for psychosis. 
  • Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. 
  • Exploratory analysis of social cognition and neurocognition in individuals at clinical high risk for psychosis. 
  • Factor structure of the positive and negative syndrome scale (PANSS) in people at ultra high risk (UHR) for psychosis. 
  • Feasibility and pilot efficacy results from the multisite Cognitive Remediation in the Schizophrenia Trials Network (CRSTN) randomized controlled trial. 
  • First- and second-generation antipsychotics. 
  • Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus. 
  • Heterogeneity of tardive dyskinesia. A multivariate analysis. 
  • Hierarchical temporal processing deficit model of reality distortion and psychoses. 
  • Hospitalized schizophrenic patient views about seclusion. 
  • Hypothalamic-pituitary-adrenal axis dysfunction in non-clinical psychosis. 
  • Hysterical psychosis and epilepsy: differential diagnosis. 
  • Identification of patients with recent-onset psychosis in KwaZulu Natal, South Africa: a pilot study with traditional health practitioners and diagnostic instruments. 
  • Identifying clinical competencies that support rehabilitation and empowerment in individuals with severe mental illness. 
  • Impact of Service User Video Presentations on Explicit and Implicit Stigma toward Mental Illness among Medical Students in Nepal: A Randomized Controlled Trial. 
  • Impact of psychiatric comorbidity in individuals at Ultra High Risk of psychosis - Findings from the Longitudinal Youth at Risk Study (LYRIKS). 
  • Impaired Context Processing is Attributable to Global Neuropsychological Impairment in Schizophrenia and Psychotic Bipolar Disorder. 
  • Implementing the protocol of a pilot randomized controlled trial for the recovery-oriented intervention to people with psychoses in two Latin American cities. 
  • In the eye of the beholder: Perceptions of neighborhood adversity and psychotic experiences in adolescence. 
  • Increased morbid risk for schizophrenia-related disorders in relatives of schizotypal personality disordered patients. 
  • Increased pituitary volume in ...psychosis study. 
  • Initial level of care and clinical status in a managed mental health program. 
  • Insight in first-episode psychosis. 
  • Interpersonal trauma, war zone exposure, and posttraumatic stress disorder among veterans with schizophrenia. 
  • Lack of Evidence for Regional Brain Volume or Cortical Thickness Abnormalities in Youths at Clinical High Risk for Psychosis: Findings From the Longitudinal Youth at Risk Study. 
  • Large-Scale Network Topology Reveals Heterogeneity in Individuals With at Risk Mental State for Psychosis: Findings From the Longitudinal Youth-at-Risk Study. 
  • Latent Profile Analysis and Conversion to Psychosis: Characterizing Subgroups to Enhance Risk Prediction. 
  • Lifetime comorbidity, lifetime history of psychosis and suicide attempts, and current symptoms of patients with deteriorated affective disorder. 
  • Links between research findings and the future of assertive community treatment: a commentary. 
  • Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis. 
  • Longitudinal Cognitive Changes in Young Individuals at Ultrahigh Risk for Psychosis. 
  • Management of Gardner-Diamond syndrome with therapeutic plasma exchange. 
  • Managing common behavioral problems in dementia. How to improve quality of life for patients and families. 
  • Medication nonadherence and substance abuse in psychotic disorders: impact of depressive symptoms and social stability. 
  • Medication preferences and adherence among individuals with severe mental illness and psychiatric advance directives. 
  • Mental Health and Functional Outcomes in Young Adulthood of Children With Psychotic Symptoms: A Longitudinal Cohort Study. 
  • Mental disorders and violence in a total birth cohort: results from the Dunedin Study. 
  • Mental health problems in juvenile justice populations. 
  • Metabolic dysfunctions in the kynurenine pathway, noradrenergic and purine metabolism in schizophrenia and bipolar disorders. 
  • Metabolic effects associated with atypical antipsychotic treatment in the developmentally disabled. 
  • Metformin for weight loss and metabolic control in overweight outpatients with schizophrenia and schizoaffective disorder. 
  • Methodological issues in assertive community treatment studies. 
  • Methylomic analysis of monozygotic twins discordant for childhood psychotic symptoms. 
  • Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. 
  • Neuropsychiatric Issues in Parkinson's Disease. 
  • Neuropsychiatric disturbance in Alzheimer's disease clusters into three groups: the Cache County study. 
  • Neuropsychiatric manifestations of porphyria. 
  • Neuropsychological impairments in schizophrenia and psychotic bipolar disorder: findings from the Bipolar-Schizophrenia Network on Intermediate Phenotypes (B-SNIP) study. 
  • Neuropsychological performance at the age of 13 years and adult schizophreniform disorder: prospective birth cohort study. 
  • Neuropsychological status of subjects at high risk for a first episode of psychosis. 
  • Neuropsychology of the prodrome to psychosis in the NAPLS consortium: relationship to family history and conversion to psychosis. 
  • No evidence for the presence of genetic variants predisposing to psychotic disorders on the non-deleted 22q11.2 allele of VCFS patients. 
  • Nondisease-specific problems and all-cause mortality in the REasons for Geographic and Racial Differences in Stroke study. 
  • Olanzapine and haloperidol in first episode psychosis: two-year data. 
  • Olanzapine in refractory schizophrenia after failure of typical or atypical antipsychotic treatment: an open-label switch study. 
  • Olanzapine, new-onset diabetes mellitus, and risk for insulin overdose. 
  • On sample size calculation based on odds ratio in clinical trials. 
  • Optimal dose of neuroleptic in acute schizophrenia. A controlled study of the neuroleptic threshold and higher haloperidol dose. 
  • Orbitofrontal cortex volume and intrinsic religiosity in non-clinical psychosis. 
  • Performance and interview-based assessments of cognitive change in a randomized, double-blind comparison of lurasidone vs. ziprasidone. 
  • Pharmacologic treatment of psychiatric disease in pregnancy and lactation: fetal and neonatal effects. 
  • Pharmacological management of first-episode schizophrenia and related nonaffective psychoses. 
  • Physical activity level and medial temporal health in youth at ultra high-risk for psychosis. 
  • Polygenic risk for schizophrenia and measured domains of cognition in individuals with psychosis and controls. 
  • Polypharmacy in pregnant women with major psychiatric illness: a pilot study. 
  • Postpartum psychiatric syndromes. 
  • Practical issues in the use of electroconvulsive therapy (ECT). 
  • Predicting suicidal risk in schizophrenic and schizoaffective patients in a prospective two-year trial. 
  • Predictors of antipsychotic treatment response in patients with first-episode schizophrenia, schizoaffective and schizophreniform disorders. 
  • Predictors of treatment discontinuation and medication nonadherence in patients recovering from a first episode of schizophrenia, schizophreniform disorder, or schizoaffective disorder: a randomized, double-blind, flexible-dose, multicenter study. 
  • Preserved working memory and altered brain activation in persons at risk for psychosis. 
  • Principal components of heritability from neurocognitive domains differ between families with schizophrenia and control subjects. 
  • Progressive Decline in Hippocampal CA1 Volume in Individuals at Ultra-High-Risk for Psychosis Who Do Not Remit: Findings from the Longitudinal Youth at Risk Study. 
  • Promoting mental health recovery and improving clinical assessment using video technology. 
  • Protective factors for psychotic experiences amongst adolescents exposed to multiple forms of victimization. 
  • Psychiatric and psychosocial correlates of sexual risk behavior among adults with severe mental illness. 
  • Psychiatric disorders from childhood to adulthood in 22q11.2 deletion syndrome: results from the International Consortium on Brain and Behavior in 22q11.2 Deletion Syndrome. 
  • Psychiatric disorders in inhalant users: results from The National Epidemiologic Survey on Alcohol and Related Conditions. 
  • Psychosis in Parkinson's disease: diagnosis and treatment. 
  • Psychotic disorder in a patient with central and extrapontine myelinolysis. 
  • Psychotic disorders cause the greatest mortality disparity among mental disorders, though more deaths are attributable overall to mood and anxiety disorders. 
  • Psychotic experiences and risk of death in the general population: 24-27 year follow-up of the Epidemiologic Catchment Area study. 
  • Quality of life during treatment with haloperidol or olanzapine in the year following a first psychotic episode. 
  • Regressing to Prior Response Preference After Set Switching Implicates Striatal Dysfunction Across Psychotic Disorders: Findings From the B-SNIP Study. 
  • Reliability and validity of the SF-12 health survey among people with severe mental illness. 
  • Religious coping and quality of life among individuals living with schizophrenia. 
  • Research on religion, spirituality, and mental health: a review. 
  • Retinal microvessels reflect familial vulnerability to psychotic symptoms: A comparison of twins discordant for psychotic symptoms and controls. 
  • Richard Dadd and the Fairy Feller's Master-Stroke. 
  • Seclusion on an adolescent unit. 
  • Self-reported sleep disturbances associated with procedural learning impairment in adolescents at ultra-high risk for psychosis. 
  • Sleep disturbance in euthymic bipolar patients. 
  • Sleep dysfunction and thalamic abnormalities in adolescents at ultra high-risk for psychosis. 
  • Smoking and psychosis in patients with bipolar I disorder. 
  • Social cognition as a mediator between neurocognition and functional outcome in individuals at clinical high risk for psychosis. 
  • Social functioning in urban, predominantly African American, socially disadvantaged patients with first-episode nonaffective psychosis. 
  • Spanish validation of the Brief Assessment in Cognition in Schizophrenia (BACS) in patients with schizophrenia and healthy controls. 
  • Specificity of childhood psychotic symptoms for predicting schizophrenia by 38 years of age: a birth cohort study. 
  • Spirituality and religion in outpatients with schizophrenia: a multi-site comparative study of Switzerland, Canada, and the United States. 
  • Stigma and treatment delay in first-episode psychosis: a grounded theory study. 
  • Storm clouds over the public mental health safety net. 
  • Striatal abnormalities and spontaneous dyskinesias in non-clinical psychosis. 
  • Structured lifestyle education to support weight loss for people with schizophrenia, schizoaffective disorder and first episode psychosis: the STEPWISE RCT. 
  • Subsyndromal and syndromal depressive symptoms among older adults with schizophrenia spectrum disorder: Prevalence and associated factors in a multicenter study. 
  • Subthreshold Psychosis in 22q11.2 Deletion Syndrome: Multisite Naturalistic Study. 
  • Taking the wrong drugs: the role of substance abuse and medication noncompliance in violence among severely mentally ill individuals. 
  • Test-retest reliability of the dot test of visuospatial working memory in patients with schizophrenia and controls. 
  • The Cognitive Assessment Interview (CAI): reliability and validity of a brief interview-based measure of cognition. 
  • The Function Biomedical Informatics Research Network Data Repository. 
  • The Longitudinal Youth at Risk Study (LYRIKS)--an Asian UHR perspective. 
  • The MATRICS Consensus Cognitive Battery, part 1: test selection, reliability, and validity. 
  • The MCCB impairment profile for schizophrenia outpatients: results from the MATRICS psychometric and standardization study. 
  • The Role of Cognition and Social Functioning as Predictors in the Transition to Psychosis for Youth With Attenuated Psychotic Symptoms. 
  • The SNAP-25 gene may be associated with clinical response and weight gain in antipsychotic treatment of schizophrenia. 
  • The Singapore flagship programme in translational and clinical research in psychosis. 
  • The chronically mentally ill in primary care. 
  • The course of cognitive functioning over six months in individuals at clinical high risk for psychosis. 
  • The experience of care partners of patients with Parkinson's disease psychosis. 
  • The impact of eszopiclone on sleep and cognition in patients with schizophrenia and insomnia: a double-blind, randomized, placebo-controlled trial. 
  • The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. 
  • The ketogenic diet and remission of psychotic symptoms in schizophrenia: Two case studies. 
  • The period of untreated psychosis before treatment initiation: a qualitative study of family members' perspectives. 
  • The response of an assertive community treatment program following a natural disaster. 
  • The severely mentally ill in general hospital psychiatric units. 
  • The social-environmental context of violent behavior in persons treated for severe mental illness. 
  • Three children with a syndrome of obesity and overgrowth, atypical psychosis, and seizures: a problem in neuropsychopharmacology. 
  • Treatment of thyrotoxicosis-induced psychosis. 
  • Unitary construct of generalized cognitive ability underlying BACS performance across psychotic disorders and in their first-degree relatives. 
  • Use of lamotrigine in a patient with a clozapine-related seizure. 
  • Utility of the Faschingbauer abbreviated MMPI as a function of patient group and sex. 
  • Validation of the German version of the brief assessment of cognition in Schizophrenia (BACS) - preliminary results. 
  • Validity of the NIMH Diagnostic Interview Schedule for Children: a comparison between psychiatric and pediatric referrals. 
  • Violence and severe mental disorder in clinical and community populations: the effects of psychotic symptoms, comorbidity, and lack of treatment. 
  • Violent behavior preceding hospitalization among persons with severe mental illness. 
  • Virtual reality assessment of functional capacity in the early course of schizophrenia: Associations with cognitive performance and daily functioning. 
  • Whole blood serotonin relates to violence in an epidemiological study. 
  • Why Are Children in Urban Neighborhoods at Increased Risk for Psychotic Symptoms? Findings From a UK Longitudinal Cohort Study. 
  • Working memory impairment in probands with schizoaffective disorder and first degree relatives of schizophrenia probands extend beyond deficits predicted by generalized neuropsychological impairment. 
• 

  Keywords of People

  • Bradford, Daniel William, Professor of Psychiatry and Behavioral Sciences, Psychiatry, Child & Family Mental Health & Community Psychiatry
  • Wu, Li-Tzy, Professor in Psychiatry and Behavioral Sciences, Medicine, General Internal Medicine